Adding pembrolizumab (Keytruda) to standard-of-care chemotherapy, followed by maintenance pembrolizumab, led to a reduction in risk of disease progression or death in patients with advanced or recurr. Read More
In 2 MMR Cohorts, Pembrolizumab/Chemotherapy Benefits Survival in Advanced Endometrial Cancer – Targeted Oncology
